CANTON, Conn., September 18, 2025 – Kelyniam Global, Inc., a leader in custom cranial and craniofacial implant solutions, announced today that it has received FDA 510(k) clearance for its Fusion™ BCP-PEEK cranial and craniofacial implants. This marks the first time the FDA has approved the use of Biphasic Calcium Phosphate (BCP) reinforced with Polyether Ether Ketone (PEEK) in cranial and craniofacial implants—representing the first major material innovation in this surgical space in over eight years.
Science Significance
The Fusion™ BCP-PEEK implant represents a groundbreaking advancement in biomaterials for cranial reconstruction. By combining the bone-regenerative properties of BCP with the mechanical strength and durability of PEEK, the implant is designed to encourage bone integration while maintaining structural resilience. This dual-material innovation could set a new standard in regenerative implant technology for neurosurgery and craniofacial reconstruction.
Regulatory Significance
The FDA’s 510(k) clearance signals regulatory confidence in both the safety and effectiveness of this unique material combination. As the first new implant material cleared for cranial and craniofacial use in nearly a decade, Fusion™ BCP-PEEK sets a precedent for how next-generation biomaterials may be evaluated and adopted in the highly regulated medical device sector. This approval also underscores the FDA’s willingness to support innovations that balance regenerative capability with long-term stability.
Business Significance
Advertisement
For Kelyniam Global, this clearance reinforces its position as an innovation-driven leader in neurosurgical implant technology. The company can now market the first U.S.-cleared BCP-PEEK cranial implant, differentiating itself from competitors reliant solely on PEEK or hydroxyapatite materials. This product also complements Kelyniam’s existing regenerative implant line—including CustomizedBone™ (hydroxyapatite) implants from Finceramica, SpA, and Osteopore’s product range—strengthening its portfolio and market share. By enabling custom design, manufacturing, and delivery within 24–48 hours, Kelyniam enhances its value proposition to surgeons and hospitals seeking both speed and innovation.
Patients’ Significance
Patients with traumatic cranial injuries, congenital defects, or defects from tumor resections stand to benefit significantly. The Fusion™ BCP-PEEK implant offers personalized fit, rapid production, and the potential for better bone integration, which may lead to improved healing outcomes and reduced long-term complications. For patients facing functional and aesthetic challenges, this innovation delivers both medical and quality-of-life improvements.
Policy Significance
The clearance highlights how U.S. regulatory pathways such as 510(k) can accelerate access to novel implant technologies when supported by robust safety and performance data. As healthcare systems push toward value-based care and regenerative solutions, innovations like Fusion™ BCP-PEEK could influence future policy discussions around reimbursement, standard-of-care guidelines, and regulatory frameworks for hybrid biomaterials. This development may also encourage broader public-private collaboration to foster biomaterial innovation in neurosurgical and orthopedic applications.
Transaction Highlights
Kelyniam Global, Inc. has achieved a significant milestone with the FDA 510(k) clearance of its Fusion™ BCP-PEEK cranial and craniofacial implants, marking the first approval of this unique material combination for use in cranial and craniofacial procedures. The Fusion™ BCP-PEEK implant is the first entirely new implant technology introduced into this market in over eight years, combining the regenerative properties of Biphasic Calcium Phosphate with the durability of Polyether Ether Ketone to support bone integration and long-term stability. Designed for custom, patient-specific applications, the implants can be manufactured and delivered within 24–48 hours, ensuring timely treatment for patients with traumatic injuries, tumor resections, or congenital conditions. This approval further expands Kelyniam’s regenerative product line, which already includes the CustomizedBone™ hydroxyapatite implant from Finceramica and the Osteopore range of products, reinforcing its leadership in advancing personalized and regenerative implant solutions.
Source: Kelyniam Global Inc Press Release
